The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
Abstract
Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). Brivanib, a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor signaling, may improve the effectiveness of TACE when given as an adjuvant to TACE. In this multinational, randomized, double-blind, placebo-controlled, phase III study, 870 patients with TACE-eligible HCC were planned to be randomly assigned (1:1) after the first TACE to receive either brivanib 800 mg or placebo orally once-daily. The primary endpoint was overall survival (OS). Secondary endpoints included time to disease progression (TTDP; a composite endpoint based on development of extrahepatic spread or vascular invasion, deterioration of liver function or performance status, or death), time to extrahepatic spread or vascular invasion (TTES/VI), rate of TACE, and safety. Time to radiographic progression (TTP) and objective response rate were exploratory endpoints. The trial was terminated after randomization of 502 patients (brivanib, 249; placebo, 253) when two other phase III studies of brivanib in advanced HCC patients failed to meet OS objectives. At termination, median follow-up was approximately 16 months. Intention-to-treat analysis showed no improvement in OS with brivanib versus placebo (median, 26.4 [95% confidence interval {CI}: 19.1 to not reached] vs. 26.1 months [19.0-30.9]; hazard ratio [HR]: 0.90 [95% CI: 0.66-1.23]; log-rank P = 0.5280). Brivanib improved TTES/VI (HR, 0.64 [95% CI: 0.45-0.90]), TTP (0.61 [0.48-0.77]), and rate of TACE (0.72 [0.61-0.86]), but not TTDP (0.94 [0.72-1.22]) versus placebo. Most frequent grade 3-4 adverse events included hyponatremia (brivanib, 18% vs. placebo, 5%) and hypertension (13% vs. 3%). Conclusions : In this study, brivanib as adjuvant therapy to TACE did not improve OS. (Hepatology 2014;60:1697–1707)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Lo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Self-citationPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Self-citationLlovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Self-citationKudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Self-citationSergio, A., Cristofori, C., Cardin, R., Pivetta, G., Ragazzi, R., Baldan, A., Girardi, L., Cillo, U., Burra, P., Giacomin, A., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01712.x · Cited by 512
Li, X. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i19.2878 · Cited by 290
Shim, J. H., Park, J., Kim, J. H., An, M., Kong, S., Nam, B., Choi, J., Kim, H. B., Lee, W. J., & Kim, C. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00909.x · Cited by 239
Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A., Chow, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0509 · Cited by 221
Finn, R. S., Kang, Y.-K., Mulcahy, M., Polite, B. N., Lim, H. Y., Walters, I., Baudelet, C., Manekas, D., & Park, J.-W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1991 · Cited by 215
Self-citationHypoxia: A Link between Fibrogenesis, Angiogenesis, and Carcinogenesis in Liver Disease
Rosmorduc, O., & Housset, C. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255355 · Cited by 208
Schoenleber, S. J., Kurtz, D. M., Talwalkar, J. A., Roberts, L. R., & Gores, G. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605017 · Cited by 207
Allen, E., Walters, I. B., & Hanahan, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2847 · Cited by 153
Self-citationPark, J., Finn, R. S., Kim, J. S., Karwal, M., Li, R. K., Ismail, F., Thomas, M. B., Harris, R., Baudelet, C., Walters, I. B., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2011 · Cited by 148
Self-citationCai, Z., Zhang, Y., Borzilleri, R. M., Qian, L., Barbosa, S. A. L., Wei, D. D., Zheng, X., Wu, L., Fan, J., Shi, Z., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7013309 · Cited by 144
Poon, R. T., Ng, I. O., Lau, C. P.-Y., et al. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00708-5 · Cited by 131
Self-citationChemoembolization for Hepatocellular Carcinoma
Lencioni, R. A. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.05.004 · Cited by 98
Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease
Strebel, B. M., & Dufour, J. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.11.1743 · Cited by 77
Bhide, R. S., Lombardo, L. J., Hunt, J. T., Cai, Z., Barrish, J. C., Galbraith, S. M., Jeyaseelan, R., Mortillo, S., Wautlet, B. S., Krishnan, B. S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0472 · Cited by 73
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationForner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Metadata
- Authors
- Kudo, M., Han, G., Finn, R. S., Poon, R. T. P., Blanc, J.-F., Yan, L., Yang, J., Lu, L., Tak, W.-Y., Yu, X., Lee, J.-H., Lin, S.-M., Wu, C., Tanwandee, T., Shao, G., Walters, I. B., Cruz, C. D., Poulart, V., & Wang, J.-H.
- Venue
- Hepatology
- Published
- 2014-11
- Volume
- 60
- Issue
- 5
- Pages
- 1697-1707
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1633413258
- Cited by
- 355
- References
- 26
- FWCI
- 13.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.